DexCom(US:DXCM) Globenewswire·2025-12-04 20:48Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for alleged misleading statements and undisclosed material changes to its glucose monitoring systems during the specified Class Period [1]. Group 1: Allegations Against DexCom - Defendants allegedly made false and misleading statements regarding unauthorized design changes to the G6 and G7 continuous glucose monitoring systems, which compromised their reliability [2]. - The design changes reportedly posed a material health risk to users who relied on these devices for accurate glucose readings [2]. - DexCom is accused of overstating the enhancements and reliability of the G7 device, while downplaying the severity of issues related to adulterated devices [2]. - The company faces increased regulatory scrutiny and potential legal, reputational, and financial harm due to these allegations [2]. Group 2: Legal Process for Investors - Investors in DexCom have until December 26, 2025, to seek appointment as lead plaintiff representatives in the class action [3]. - A lead plaintiff acts on behalf of all class members and selects counsel to represent the class, with the ability to share in any recovery not affected by the decision to serve as lead plaintiff [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [5].